Physician profile
James G Avery
NPI 1487671947
$2,547.95
in general payments reported to CMS, 2019-2025
27 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,644 · 2020: $501 · 2021: $32.28 · 2023: $108 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $370.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $466.32 | 2019-2025 | Evenity |
| Radius Health, INC. | $260.80 | 2019-2025 | Tymlos |
| Pfizer INC. | $233.52 | 2019-2020 | |
| Lilly USA, LLC | $212.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $165.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $143.14 | 2019-2020 | |
| Novo Nordisk INC | $112.01 | 2019-2020 | |
| Astellas Pharma US INC | $110.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.34 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $108.42 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.00 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $62.83 | 2019-2020 | |
| Abbvie INC. | $57.32 | 2019-2021 | |
| Sanofi Pasteur INC. | $49.32 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $45.52 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43.97 | 2019 | |
| Amarin Pharma, INC. | $42.19 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $40.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.74 | 2019 | |
| Allergan, INC. | $35.12 | 2019-2020 | |
| Dynavax Technologies Corporation | $31.59 | 2019-2020 | |
| Shire North American Group INC | $30.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.61 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.45 | 2019 | |
| Gilead Sciences, INC. | $13.64 | 2019 | |
| Merck Sharp & Dohme LLC | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Avery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.